American Innovation Strikes Back: Cancer Vaccine and CAR-T Therapy Show Real Results

American ingenuity is on full display as Anixa Biosciences (NASDAQ: ANIX), a San Jose-based biotech, prepares to showcase its groundbreaking work in the fight against cancer at the 2026 Cantor Fitzgerald Global Healthcare Conference in New York City. The company is bringing real solutions to the table: a breast cancer vaccine that hits its marks and an ovarian cancer therapy that is keeping patients alive well past the one-year mark.

Breast Cancer Vaccine Passes Phase 1 with Flying Colors

This is not theoretical science. This is results. The final Phase 1 data for Anixa's breast cancer vaccine, developed in partnership with the Cleveland Clinic and funded by the U.S. Department of Defense, shows all primary endpoints were met. Protocol-defined immune responses were generated in 74% of participants. The vaccine is designed to both treat and prevent breast cancer, and Phase 2 preparations are already underway.

Dr. Amit Kumar, Chairman and CEO of Anixa, made it clear that the market is waking up to this potential. Citing the recent buzz around Merck and Moderna's melanoma vaccine, he stated:

“The recent presentation of preliminary data by Merck and Moderna for their personalized melanoma vaccine reinforces the growing potential of cancer vaccines as an important new approach to both treating and preventing cancer. Anixa is already advancing within this field with a vaccine designed to both treat and prevent breast cancer.”

Ovarian Cancer CAR-T Therapy: Patients Surviving Years, Not Months

The news on the ovarian cancer front is just as promising. Anixa's CAR-T therapy, known as lira-cel, is being tested in a Phase 1 trial with the Moffitt Cancer Center. These are not easy patients. They are highly pre-treated, recurrent, and resistant cases who have failed conventional therapies. Despite that, the therapy is now dosing at its highest level yet, incorporating lymphodepletion for the first time.

The numbers speak for themselves:

• No dose-limiting toxicities observed so far.
• Four patients have surpassed one year of survival.
• The longest survivor is at approximately 28 months.

Mike Catelani, President, COO & CFO of Anixa, summed up the mood:

“This is an exciting time for Anixa, with our breast cancer vaccine advancing toward Phase 2 and our ovarian cancer CAR-T program now dosing at the highest level evaluated in the trial.”

What Makes This Technology Different?

This is not the same old approach. Anixa's ovarian cancer therapy uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. Instead of using an antibody fragment, it uses the natural ligand of the FSHR receptor to bind to tumor cells. That is a smarter, more precise way to attack the disease.

The vaccine portfolio, also developed with the Cleveland Clinic, focuses on targeting